WLF: leave ethics out of approvals

Share this article:
Calls by bioethicists and environmentalists for the FDA to consider other decidedly unscientific factors, including ethics and healthcare costs, when deciding a product approval decision are “absurd,” according to two senior officers of the American Council on Science and Health writing in a Washington Legal Foundation legal opinion letter. They were responding to an earlier article appearing in the Baltimore Sun.
They claim there are already “too many non-science factors working on FDA drug professionals. ... The intrusion of ‘ethics' into the drug evaluation process would lead to increased regulation of the drug industry, probably to the point of regulating it out of existence.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?